-
REAL-WORLD SAFETY AND OUTCOMES OF BISPECIFIC ANTIBODIES IN OLDER ADULTS
Feb 25, 2026, 14:41 PM -
PREDICTORS OF INITIATING MEDICATIONS FOR OPIOID USE DISORDER IN THE EMERGENCY DEPARTMENT: A RETROSPECTIVE COHORT STUDY
Feb 25, 2026, 14:41 PM -
PATIENT-REPORTED OUTCOMES-BASED SYMPTOM MONITORING AMONG PATIENTS RECEIVING IMMUNOTHERAPY FOR LUNG CANCER: A RANDOMIZED CONTROLLED TRIAL
Feb 25, 2026, 14:41 PM -
AN EFFECTIVE METHODOLOGICAL FRAMEWORK FOR EXECUTING MULTINATIONAL, PATIENT-CENTRED CROSS-SECTIONAL SURVEYS IN RARE DISEASES: FACILITATING EVIDENCE GENERATION WITH GENERALISABILITY ACROSS CONDITIONS TO SUPPORT COMMERCIAL VIABILITY
Feb 25, 2026, 14:41 PM -
HEALTHCARE RESOURCE UTILIZATION OF MEDICALLY ATTENDED DENGUE IN CHILDREN AND ADULTS IN PUERTO RICO FROM 2019 TO 2025: A DESCRIPTIVE STUDY
Feb 25, 2026, 14:41 PM -
COMPARATIVE EFFECTIVENESS AND HARMS OF SUSTAINED STATIN THERAPY AMONG YOUNG ADULTS
Feb 25, 2026, 14:41 PM -
ARTIFICIAL INTELLIGENCE (AI) IN ONCOLOGY HEALTH TECHNOLOGY ASSESSMENT (HTA): CURRENT APPLICATIONS, LIMITATIONS, AND IMPLICATIONS FOR LIVING-HTA
Feb 25, 2026, 14:41 PM -
HEALTHCARE BURDEN IN PATIENTS WITH HIDRADENITIS SUPPURATIVA: A SYSTEMATIC REVIEW
Feb 25, 2026, 14:41 PM -
A LIFETIME COST-UTILITY ANALYSIS OF IGLARLIXI VERSUS IDEGASP IN TYPE 2 DIABETES IN TURKIYE
Feb 25, 2026, 14:41 PM -
GENERATIVE ARTIFICIAL INTELLIGENCE FOR AUTOMATED HEALTH ECONOMIC MODEL DEVELOPMENT: A PROOF-OF-CONCEPT FRAMEWORK
Feb 25, 2026, 14:41 PM -
FROM TOKYO TO WASHINGTON: IMPACT OF JAPAN’S HTA ENVIRONMENT ON U.S. MFN PRICING AND LAUNCH STRATEGY
Feb 25, 2026, 14:41 PM -
BUILDING RESILIENCY IN LIFE SCIENCES RESEARCH ORGANIZATIONS
Feb 25, 2026, 14:41 PM -
PSYCHOMETRIC EVALUATION OF A NOVEL PATIENT-PROVIDER TOOL FOR ASSESSING DIABETES SELF-MANAGEMENT KNOWLEDGE AND BEHAVIOR IN ADULTS WITH TYPE 2 DIABETES MELLITUS
Feb 25, 2026, 14:41 PM -
BUDGET IMPACT ANALYSIS OF KIRSTY AND MERILOG IN THE TREATMENT OF DIABETES MELLITUS FROM A U.S. PAYER PERSPECTIVE
Feb 25, 2026, 14:41 PM -
EARLY PATTERNS IN SECOND ORPHAN DRUG DESIGNATIONS FOLLOWING EXPANSION OF THE ORPHAN DRUG EXCLUSION
Feb 25, 2026, 14:41 PM -
THE ECONOMIC IMPACT OF PERIOPERATIVE IMMUNE CHECKPOINT INHIBITORS IN RESECTABLE GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCERS IN A CANADIAN SETTING
Feb 25, 2026, 14:41 PM -
A COMPARISON OF DIRECT MEDICAL COSTS IN VERTEBROPLASTY AND KYPHOPLASTY IN JAPAN AND IMPLICATIONS FOR IMPACTS ON THE BUDGET
Feb 25, 2026, 14:41 PM -
CONTRASTIVE TRAJECTORY DISTILLATION: A NOVEL METHOD FOR OPTIMIZING LARGE LANGUAGE MODEL EMBEDDINGS IN MATERNAL HEALTH PREDICTION
Feb 25, 2026, 14:41 PM -
MULTI-INDICATION BUDGET IMPACT ANALYSIS OF SUBCUTANEOUS IGPRO20 PRE-FILLED SYRINGES FOR THE TREATMENT OF PID, SID, AND CIDP IN ITALY
Feb 25, 2026, 14:41 PM -
A U.S.-SPECIFIC BUDGET IMPACT MODEL (BIM) OF SEMAGLUTIDE 2.4 MG IN THE TREATMENT OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) USING MOST FAVORED NATION (MFN) PRICING
Feb 25, 2026, 14:41 PM
